Collaborative Approach to the Community

The ADCS serves as a scientific resource to support academic investigators, biotech companies, and other Principal Investigators (PIs) who have interventions that they wish to test in multicenter clinical trials that could benefit from collaboration with the ADCS. Over the last 5 years, the ADCS has evolved an interactive process whereby it can receive interest from PIs or other collaborators, to present to its Intervention Selection Committee (ISC) where a program review and proposed collaboration is undertaken with follow-up feedback to the presenters. This ADCS review follows an evaluation framework, developed by the ISC members, and benefits from the breadth of expertise of its members including preclinical, and clinical expertise in drug development as well as in lifestyle or multidomain interventions. The committee chair provides feedback to those presenters after receiving back and collating reviews of the ISC. It is focused on next steps and sets up ongoing dialogue that can continue through the early development of the compounds or programs being presented.

To date, the ADCS ISC has advanced three programs from early discussions with to collaborations that include the ADCS undertaking POC multicenter clinical trials utilizing the network infrastructure of sites of the ADCS across the United States.

Purpose

The ISC is constituted to evaluate potential programs of interest for ADCS collaborations. This may include programs brought to the ADCS by commercial sponsors including pharma and biotech, by academic investigators, and fosters these collaborations. The ADCS has developed an evaluation framework for this purpose and is constituted with broad cross-functional expertise to address pharmaceutical as well as non-pharmaceutical/behavioral/social interventions. The ISC has members with expertise in each of these respective areas.

Responsibilities of Members

Members will be asked to review materials, participate in monthly meetings, provide program evaluations, alternate taking the lead in the presentation of new programs, and at quarterly ADCS Steering Committee Meetings as applicable where updates on the collaboration pipeline are presented.

Term of Membership

3 years with option to continue or step-down.

Membership Selection Process

Potential new members are recommended and brought forward by current committee members and ADCS Associate Directors.

If you are interested in presenting your program to the ISC please contact the committee chair, Dr. Howard Feldman at howardfeldman@ucsd.edu to schedule an initial discussion.

Committee Members

Howard Feldman

Howard Feldman

Chair

University of California, San Diego

Steve Arnold

Steve Arnold

Harvard University/Massachusetts General Hospital

Aaron Burstein

Aaron Burstein

Alzheimer’s Drug Discovery Foundation

Xu Chen

Xu Chen

University of California, San Diego

Doug Galasko

Doug Galasko

University of California, San Diego

Li Gan

Li Gan

Weill Cornell Medicine

Lawrence Goldstein

Lawrence Goldstein

University of California, San Diego

Barry Greenberg

Barry Greenberg

Johns Hopkins University

Judy Pa

Judy Pa

University of California, San Diego

Lon Schneider

Lon Schneider

University of Southern California

Stacey Sukoff Rizzo

Stacey Sukoff Rizzo

University of Pittsburgh

Malú Tansey

Malú Tansey

Indiana University

Paul Territo

Paul Territo

Indiana University

Erika Weekman

Erika Weekman

Indiana University

Steve Wagner

Steve Wagner

In Memoriam

Eddie Koo

Eddie Koo

In Memoriam